PE20010212A1 - COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM - Google Patents

COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM

Info

Publication number
PE20010212A1
PE20010212A1 PE2000000521A PE0005212000A PE20010212A1 PE 20010212 A1 PE20010212 A1 PE 20010212A1 PE 2000000521 A PE2000000521 A PE 2000000521A PE 0005212000 A PE0005212000 A PE 0005212000A PE 20010212 A1 PE20010212 A1 PE 20010212A1
Authority
PE
Peru
Prior art keywords
peptide
composition
solubilize
refers
sufficient
Prior art date
Application number
PE2000000521A
Other languages
Spanish (es)
Inventor
Pamela Hirtzer
Naina Patel
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of PE20010212A1 publication Critical patent/PE20010212A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UNA SOLUCION ACUOSA DE POR LO MENOS 0,01 mg/ml DE PEPTIDO ß AMILOIDE (Aß), DE PREFERENCIA LA FORMA LARGA; Aß42; CONFORMACION ESPIRALADA; UN BUFFER QUE MANTIENE EL pH ALREDEDOR 8,5 A 12 O SUFICIENTE PARA SOLUBILIZAR DICHO PEPTIDO Aß DE PREFERENCIA AMINOACIDOS, SALES, ALCALINIZANTES ACEPTABLES, HIDROXIDOS DE METALES ALCALINOS E HIDROXIDOS DE AMONIO, ACIDOS ORGANICOS; ADYUVANTE INCOMPLETO DE FREUND, 3 DE O-ACIL MONOFOSFORIL LIPIDO A (MPL), GLICOSIDO TRITERPENICO (QS21) Y ALUMBRE; 10mM DE GLICINA; 20mM DE CITRATO DE SODIO; 5% DE SACAROSA; ENTRE 0,9%(m/v) Y 6%(m/v) DE UN AGENTE DE TONICIDAD; ENTRE 0,05%(m/v) Y 0,5%(m/v) DE UN TENSOACTIVO, ENTRE 0,1mM Y 1mM DE UN AGENTE QUELANTE. TAMBIEN SE REFIERE A UNA COMPOSICION LIOFILIZADA DEL PEPTIDO Aß EN DONDE DICHA SOLUCION SE MANTIENE A UN pH SUFICIENTE PARA SOLUBILIZAR EL PEPTIDO; LIOFILIZAR LA COMPOSICION CONGELADA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMERIT REFERS TO A COMPOSITION THAT INCLUDES AN AQUEOUS SOLUTION OF AT LEAST 0.01 mg / ml OF PEPTIDE ß AMYLOID (Aß), PREFERABLY THE LONG FORM; Aß42; SPIRAL CONFORMATION; A BUFFER THAT MAINTAINS THE pH AROUND 8.5 TO 12 OR SUFFICIENT TO SOLUBILIZE SAID Aß PEPTIDE OF PREFERENCE AMINO ACIDS, SALTS, ACCEPTABLE ALKALINIZERS, ALKALINE METAL HYDROXIDES AND AMMONIUM HYDROXIDES, ORGANIC ACIDS; FREUND'S INCOMPLETE ADJUVANT, 3-O-ACIL MONOPHOSPHORYL LIPID A (MPL), TRITERPENIC GLYCOSIDE (QS21) AND ALUM; 10mM GLYCINE; 20mM SODIUM CITRATE; 5% SACROSE; BETWEEN 0.9% (m / v) AND 6% (m / v) OF A TONICITY AGENT; BETWEEN 0.05% (m / v) AND 0.5% (m / v) OF A SURFACTANT, BETWEEN 0.1mM AND 1mM OF A CHELATING AGENT. IT ALSO REFERS TO A LYOPHILIZED COMPOSITION OF THE Aß PEPTIDE, WHERE SAID SOLUTION IS KEPT AT A SUFFICIENT pH TO SOLUBILIZE THE PEPTIDE; FREEZE THE FROZEN COMPOSITION. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE

PE2000000521A 1999-06-01 2000-05-31 COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM PE20010212A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
PE20010212A1 true PE20010212A1 (en) 2001-02-22

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000521A PE20010212A1 (en) 1999-06-01 2000-05-31 COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM

Country Status (25)

Country Link
EP (1) EP1181040A1 (en)
JP (1) JP2003519620A (en)
KR (1) KR20020016813A (en)
CN (1) CN1353615A (en)
AR (1) AR024558A1 (en)
AU (1) AU5726100A (en)
BG (1) BG106249A (en)
BR (1) BR0011251A (en)
CA (1) CA2374897A1 (en)
CZ (1) CZ20014150A3 (en)
EE (1) EE200100649A (en)
HK (1) HK1045938A1 (en)
HR (1) HRP20010901A2 (en)
IL (1) IL146575A0 (en)
IS (1) IS6182A (en)
MX (1) MXPA01012355A (en)
NO (1) NO20015859L (en)
NZ (1) NZ515744A (en)
PE (1) PE20010212A1 (en)
PL (1) PL352575A1 (en)
RU (1) RU2001135800A (en)
SK (1) SK17012001A3 (en)
TR (1) TR200103476T2 (en)
WO (1) WO2000072870A1 (en)
ZA (1) ZA200109704B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
NO347079B1 (en) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Improved protofibril-selective antibodies and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
DK3166970T3 (en) 2014-07-10 2021-05-25 Bioarctic Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
CN114957438B (en) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016819A1 (en) * 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
HRP20010901A2 (en) 2003-04-30
AU5726100A (en) 2000-12-18
KR20020016813A (en) 2002-03-06
MXPA01012355A (en) 2003-06-24
CN1353615A (en) 2002-06-12
NO20015859L (en) 2002-02-01
BG106249A (en) 2002-08-30
EE200100649A (en) 2003-02-17
CA2374897A1 (en) 2000-12-07
IS6182A (en) 2001-11-29
CZ20014150A3 (en) 2002-05-15
ZA200109704B (en) 2003-02-26
BR0011251A (en) 2002-03-05
EP1181040A1 (en) 2002-02-27
IL146575A0 (en) 2002-07-25
SK17012001A3 (en) 2002-06-04
AR024558A1 (en) 2002-10-16
NZ515744A (en) 2004-04-30
RU2001135800A (en) 2003-08-20
WO2000072870A1 (en) 2000-12-07
TR200103476T2 (en) 2002-04-22
NO20015859D0 (en) 2001-11-30
JP2003519620A (en) 2003-06-24
HK1045938A1 (en) 2002-12-20
PL352575A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
PE20010212A1 (en) COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM
FI80598C (en) FOERFARANDE FOER FRAMSTAELLNING AV EN ENZYMBEREDNING.
AR024074A1 (en) ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES.
BR0210721A (en) Pharmaceutically acceptable compound, salt or ester, method for making a compound, and method for treating a patient having, or preventing the patient from acquiring a disease or condition.
PE84799A1 (en) IMPROVED METHODS FOR THE PROCESSING OF ACTIVATED C PROTEIN
CL2004000782A1 (en) PARENTERAL PHARMACEUTICAL COMPOSITION THAT INCLUDES (A) PIPERACILLIN, (B) TAZOBACTAMO, AND A CHELATING AMINOCARBOXYLIC ACID, WHICH ALSO CAN CONTAIN A TAMPON, AS CITRATE, AND OPTIONALLY AN AMINOGLYCOSIDE; PROCEDURES FOR PREPARATION; AND USE
ECSP024352A (en) NEW PHARMACEUTICAL COMPOSITION
ATE284415T1 (en) MUTATED VARIANT OF INSULIN-LIKE GROWTH FACTOR-I (IGF-I)
EA199900778A1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE TO INHIBIT β-AMYLOID PEPTIDE
DE60138468D1 (en) CYANOPHENOXY CARBOXYLIC ACIDS AND COMPOSITIONS FOR THE RELEASE OF ACTIVE SUBSTANCES
FR2627696B1 (en) NEW GALENIC FORM OF FENOFIBRATE
BR0213139A (en) Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
ES2168334T3 (en) COMPOSITION FOR SKIN TREATMENT.
BR9914940A (en) Method to improve the pharmacokinetics of tipranavir
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
SE0002202D0 (en) New peptides
AR039857A1 (en) PREPARATIONS OF A SULFINYL ACETAMIDE
PE20060769A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING A SALT OF A SOMATOSTATIN ANALOGUE
PA8542901A1 (en) USE OF (Z) -2-CIANO-3-HYDROXI-BUT-2-ENOIC ACID- (4-TRIFLUOROMETILFENIL) -AMIDA TO TREAT MULTIPLE SCLEROSIS
CO5570658A2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
NZ535032A (en) Lyophilised, stable pharmaceutical composition containing factor VIII, which comprises trisodium citrate, but is devoid of amino acids
AR002018A1 (en) OPTICALLY ACTIVE BENZOTIEPINE DERIVATIVE; METHOD TO PRODUCE IT; OPTICALLY ACTIVE COMPOUND FOR USE IN SUCH METHOD; DEOSTEOGENESIS PROMOTER, AGENT TO PREVENT OR TREAT BONE DISEASES, PROMOTER FOR THE TREATMENT OF BONE FRACTURE, METHOD OF TREATMENT AND
KR970706839A (en) A pharmaceutical composition comprising growth hormone and isoleucine (A PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND ISOLEUCINE)
FR2647677B1 (en) NOVEL MICRO-PROTEINS, PROCESS FOR THE PREPARATION AND APPLICATION AS MEDICAMENTS OF SUCH NEW MICRO-PROTEINS
ATE409493T1 (en) PEPTIDE COMPOSITIONS FOR THE TREATMENT OF PERIODONTAL DISEASES AND PREVENTION OF SKIN AGING

Legal Events

Date Code Title Description
FC Refusal